Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ilana Yanai-Inbar is active.

Publication


Featured researches published by Ilana Yanai-Inbar.


Fertility and Sterility | 1978

Suppressive Effect of 1,2-Dibromo-3-Chloropropane on Human Spermatogenesis

Gad Potashnik; Noach Ben-Aderet; Raphael Israeli; Ilana Yanai-Inbar; Ivor Sober

Azoospermia was diagnosed in six factory workers who had been chronically exposed to 1,2-dibromo-3-chloropropane. Infertility was the presenting symptom in two patients and a decrease in libido or impotence characterized the others. Hormone studies revealed elevated plasma follicle-stimulating hormone levels and normal plasma luteinizing hormone and testosterone concentrations. Testicular biopsy showed selective atrophy of the germinal epithelium, intact Sertoli cells, and a normal appearance of a relatively increased number of Leydig cells.


Journal of Endodontics | 1991

Effects of Sodium Hypochlorite on Soft Tissues after Its Inadvertent Injection beyond the Root Apex

Albert Gatot; Jonathan Arbelle; Alberto Leiberman; Ilana Yanai-Inbar

The effects of an inadvertent injection of sodium hypochlorite into the cheek during irrigation of the right maxillary central incisor root canal are reported. The patient suffered from severe pain, edema, and necrosis of subcutaneous tissues and mucosa. Surgical intervention was necessary to contain the destructive process which extended from the upper lip to the right eye. The histopathological examination demonstrated the high cytotoxicity of sodium hypochlorite on vital tissue.


Fertility and Sterility | 1987

Dibromochloropropane (DBCP): An 8-year reevaluation of testicular function and reproductive performance

Gad Potashnik; Ilana Yanai-Inbar

The current study summarizes an 8-year reassessment of testicular function and reproductive performance in 15 workers with dibromochloropropane (DBCP)-induced azoospermia and oligozoospermia. Recovery of spermatogenesis was observed in four oligozoospermic and three azoospermic men whose plasma follicle-stimulating hormone (FSH) concentration was normal during the whole period. A marked increase in FSH and luteinizing hormone concentrations above the upper limit of normal was found in the azoospermic workers who did not recover. No significant changes in FSH concentrations were detected in both recovered and nonrecovered oligozoospermic men. Testosterone levels of all patients were normal at all times. Paternal exposure to DBCP was not associated with increased risk of fetal malformations or spontaneous abortion.


European Journal of Obstetrics & Gynecology and Reproductive Biology | 1999

Abnormal uterine bleeding as a presenting sign of metastases to the uterine corpus, cervix and vagina in a breast cancer patient on tamoxifen therapy.

Benjamin Piura; Ilana Yanai-Inbar; Alex Rabinovich; Svetlana Zalmanov; Jed Goldstein

Metastases to the female genital tract from extragenital cancers are uncommon. The ovaries are most often affected with the breast and gastrointestinal tract being the most common sites of the primary malignancy. Metastases to the uterus from extragenital cancers are significantly rarer than metastases to the ovaries and in the majority of cases the ovaries are also involved. A case of metastases restricted to the uterine corpus, cervix and vagina from breast carcinoma, without involvement of the ovaries, is described. The patient who had been on tamoxifen therapy presented with postmenopausal bleeding. The diagnosis of uterine metastases was established during endometrial ablation and confirmed by total abdominal hysterectomy and bilateral salpingo-oophorectomy. This case illustrates that abnormal uterine bleeding in a breast cancer patient, regardless of whether she is receiving or not receiving tamoxifen, should always alert the physician to consider the possibility of uterine metastases from breast carcinoma.


European Journal of Obstetrics & Gynecology and Reproductive Biology | 2003

Peritoneal tuberculosis--an uncommon disease that may deceive the gynecologist.

Benjamin Piura; Alex Rabinovich; Elad Leron; Ilana Yanai-Inbar; Moshe Mazor

OBJECTIVES To document women with peritoneal tuberculosis mimicking ovarian malignancy and to review pertinent literature. STUDY DESIGN The records of women with peritoneal tuberculosis who were managed at the Soroka Medical Center, Beer-Sheva, Israel between January 2000 and December 2001 were reviewed. RESULTS Four patients with peritoneal tuberculosis mimicking ovarian malignancy were encountered. Two presented with the classical symptomatology of advanced-stage ovarian carcinoma including ascites, abdominopelvic masses and elevated serum CA-125, and two presented with lower abdominal pain and adnexal mass. Laparoscopy in one patient and laparotomy in three patients revealed peritoneal tuberculosis and no malignancy. Of the three patients who had laparotomy, two underwent unnecessary extended surgery including total hysterectomy, bilateral salpingo-oophorectomy, omentectomy and bilateral pelvic lymphadenectomy, and one had conservative surgery including unilateral salpingo-oophorectomy. All patients were postoperatively treated with quadruple anti-tuberculosis chemotherapy. CONCLUSIONS Medical awareness of peritoneal tuberculosis is still lacking and many women with this disease are initially thought to have ovarian malignancy and undergo unnecessary extended surgery. Laparoscopy including biopsies seems to be a sufficient and safe method to provide diagnosis of peritoneal tuberculosis. If laparoscopy is not feasible, laparotomy should be performed. If no malignancy is detected and the diagnosis of peritoneal tuberculosis is confirmed, unnecessary extended surgery is avoided and anti-tuberculosis treatment is started.


International Journal of Gynecological Cancer | 1992

Epithelial ovarian tumors of borderline malignancy: a study of 50 cases

Benjamin Piura; R. Dgani; I. Blickstein; Ilana Yanai-Inbar; B. Czernobilsky; M. Glezerman

Of 50 patients with borderline epithelial ovarian tumors, 32 (64%) had serous, 17 (34%) had mucinous and one (2%) had endometrioid tumor. All patients with mucinous tumor had stage I disease, whereas 4 patients with serous tumor had stage II–III disease. Five patients (10%) were pregnant at the time of diagnosis. Seventeen patients (34%) had initial surgery with ovarian conservation and 7 of them were not subjected to further surgery. Five patients (10%) received adjuvant chemotherapy. Five-year survival and 5-year disease-free survival rates were 100% and 96.4%, respectively. It is concluded that for patients with stage IA disease unilateral salpingo-oophorectomy seems to be adequate treatment and for those with more than stage IA disease, surgery should include total abdominal hysterectomy and bilateral salpingo-oophorectomy. Although the effectiveness of chemotherapy in these tumors is uncertain, adjuvant chemotherapy is advocated for patients in whom spread of the tumor beyond the ovaries has occurred.


Journal of Surgical Oncology | 1998

Peritoneal papillary serous carcinoma: Study of 15 cases and comparison with stage iii–iv ovarian papillary serous carcinoma

Benjamin Piura; Mihai Meirovitz; Mary Bartfeld; Ilana Yanai-Inbar; Yoram Cohen

Background and Objectives: Peritoneal papillary serous carcinoma (PPSC) is histologically and clinically similar to stage III–IV ovarian papillary serous carcinoma (OPSC). The purpose of this study was to investigate the clinical findings, treatment, and outcome of PPSC patients compared with stage III–IV OPSC patients.


European Journal of Obstetrics & Gynecology and Reproductive Biology | 2001

Three primary malignancies related to BRCA mutation successively occurring in a BRCA1 185delAG mutation carrier

Benjamin Piura; Alex Rabinovich; Ilana Yanai-Inbar

The 185delAG and 5382insC mutations in the BRCA1 gene and the 6174delT mutation in the BRCA2 gene (the Ashkenazi mutations) have been found to be significantly more common among Jews of eastern European ancestry (1 in 40, 2.5%) in comparison to the general population (1 in 800 to 1 in 300, 0.12-0.33%). Carriers of these mutations, especially the BRCA1 185delAG mutation, have a significantly increased lifetime risk of breast and ovarian carcinoma and other carcinomas as compared to non-carriers. A case of three primary malignancies related to the BRCA1 185delAG mutation successively occurring in a carrier of this mutation, is described. The patient successively developed breast carcinoma, ovarian micropapillary serous carcinoma and peritoneal papillary serous carcinoma. Immunohistochemical staining results have indicated that these tumors are three separate primary malignancies. This case illustrates that ovarian serous borderline tumors (including micropapillary serous carcinoma) and peritoneal papillary serous carcinomas should be considered, like breast and ovarian carcinomas, tumors expressed in BRCA mutation carriers.


Gynecologic Oncology | 1990

Role of prolonged excessive estrogen stimulation in the pathogenesis of endometrial sarcomas: two cases and a review of the literature.

M. Altaras; Richard Jaffe; Ilan Cohen; Arieh Gruber; Ilana Yanai-Inbar; J. Bernheim

Two cases of endometrial sarcoma that developed many years after exposure to unopposed exogenous and endogenous estrogens, with no previous pelvic irradiation, are described. The literature is reviewed and the possible effect of prolonged unopposed estrogen stimulation is suggested as an etiologic factor in such extremely rare conditions. These cases add additional support to the assumption that prolonged and excessive endogenous or exogenous unopposed estrogen stimulation of the uterus may increase the risk of endometrial sarcoma.


European Journal of Obstetrics & Gynecology and Reproductive Biology | 1998

Uterine papillary serous carcinoma: study of 19 cases

Benjamin Piura; Mihai Meirovitz; Michael Shmulman; Ilana Yanai-Inbar; Yoram Cohen; Ram Dgani

OBJECTIVE Uterine papillary serous carcinoma (UPSC) is an uncommon highly malignant variant of endometrial carcinoma that histologically and clinically resembles ovarian papillary serous carcinoma. The purpose of this study was to present the conjoined experience of two regional hospitals in the south of Israel (Soroka Medical Center, Beer-Sheva and Kaplan Hospital, Rehovot) of handling this tumour. STUDY DESIGN Data from the files of 19 patients with UPSC who were managed at these hospitals between July 1991 and June 1997 were evaluated. RESULTS The three-year survival rate was 57.3% overall; 83.3% for Stage I and 21.2% for Stages II, III, and IV combined (P<0.02). Eighteen patients had primary surgery which included total abdominal hysterectomy and bilateral salpingo-oophorectomy and 15 (83.3%) of them received postoperative adjuvant therapy which included radiotherapy and/or systemic chemotherapy. CONCLUSIONS The prognosis of patients with UPSC is worse than that of patients with other forms of endometrial carcinoma. Primary surgery comprised of total abdominal hysterectomy, bilateral salpingo-oophorectomy and staging is the mainstay of treatment. The type of postoperative treatment is not consistent. By and large, adjuvant pelvic radiotherapy is usually given in early-stage disease and adjuvant systemic chemotherapy is usually prescribed in advanced-stage disease.

Collaboration


Dive into the Ilana Yanai-Inbar's collaboration.

Top Co-Authors

Avatar

Benjamin Piura

Ben-Gurion University of the Negev

View shared research outputs
Top Co-Authors

Avatar

Yoram Cohen

Ben-Gurion University of the Negev

View shared research outputs
Top Co-Authors

Avatar

Alex Rabinovich

Ben-Gurion University of the Negev

View shared research outputs
Top Co-Authors

Avatar

Marek Glezerman

Ben-Gurion University of the Negev

View shared research outputs
Top Co-Authors

Avatar

Mihai Meirovitz

Ben-Gurion University of the Negev

View shared research outputs
Top Co-Authors

Avatar

Ram Dgani

Ben-Gurion University of the Negev

View shared research outputs
Top Co-Authors

Avatar

Albert Gatot

Ben-Gurion University of the Negev

View shared research outputs
Top Co-Authors

Avatar

Dan Nemet

Ben-Gurion University of the Negev

View shared research outputs
Top Co-Authors

Avatar

Gad Potashnik

Ben-Gurion University of the Negev

View shared research outputs
Top Co-Authors

Avatar

Moshe Mazor

Ben-Gurion University of the Negev

View shared research outputs
Researchain Logo
Decentralizing Knowledge